COVUITY Trademark

Trademark Overview

On Monday, June 1, 2020, a trademark application was filed for COVUITY with the United States Patent and Trademark Office. The USPTO has given the COVUITY trademark a serial number of 88942313. The federal status of this trademark filing is REGISTERED as of Tuesday, May 31, 2022. This trademark is owned by BioNTech SE. The COVUITY trademark is filed in the Pharmaceutical Products category with the following description:

vaccines for human use for the prevention of COVID-19 and other diseases
covuity

General Information

Serial Number88942313
Word MarkCOVUITY
Filing DateMonday, June 1, 2020
Status700 - REGISTERED
Status DateTuesday, May 31, 2022
Registration Number6741967
Registration DateTuesday, May 31, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 15, 2022

Trademark Statements

Goods and Servicesvaccines for human use for the prevention of COVID-19 and other diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioNTech SE
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressMainz 55131
DE
Party NameBioNTech SE
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressMainz 55131
DE
Party NameBioNTech SE
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressMainz 55131
DE

Trademark Events

Event DateEvent Description
Tuesday, May 31, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 31, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, March 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 15, 2022PUBLISHED FOR OPPOSITION
Wednesday, February 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 9, 2022ELECTRONIC RECORD REVIEW COMPLETE
Friday, February 4, 2022ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, February 2, 2022ELECTRONIC RECORD REVIEW COMPLETE
Friday, January 21, 2022ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Friday, January 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 14, 2022EXAMINER'S AMENDMENT ENTERED
Friday, January 14, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, January 14, 2022EXAMINERS AMENDMENT E-MAILED
Friday, January 14, 2022EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 21, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 21, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 21, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, August 27, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, August 27, 2021FINAL REFUSAL E-MAILED
Friday, August 27, 2021FINAL REFUSAL WRITTEN
Tuesday, July 27, 2021ASSIGNED TO EXAMINER
Monday, July 26, 2021ASSIGNED TO EXAMINER
Tuesday, June 29, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 28, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 28, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 27, 2020NOTIFICATION OF PRIORITY ACTION E-MAILED
Sunday, December 27, 2020PRIORITY ACTION E-MAILED
Sunday, December 27, 2020PRIORITY ACTION WRITTEN
Friday, December 18, 2020PETITION TO DIRECTOR - DISMISSED
Thursday, December 17, 2020ASSIGNED TO PETITION STAFF
Wednesday, December 16, 2020ASSIGNED TO EXAMINER
Tuesday, December 8, 2020TEAS PETITION TO DIRECTOR RECEIVED
Tuesday, December 8, 2020ASSIGNED TO LIE
Wednesday, September 16, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, June 22, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, June 4, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

covuity other diseases covid prevention human vaccines